Pemvidutide achieves 15.6% weight loss at 48 weeksTopline results from the MOMENTUM Phase 2 obesity trial of pemvidutide has shown at week 48, subjects receiving pemvidutide achieved mean...
Altimmune completes dosing in the Phase 2 MOMENTUM trialAltimmune has completed dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of...
FDA approves Phase II trial for obesity-treating drug pemvidutideThe Food and Drug Administration (FDA) has approved a Phase II clinical trial for investigational obesity-treating drug pemvidutide. The...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure2 days ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity2 days ago